Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks.
The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle.
Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing development costs and execution risk may limit how quickly profits and cash flows catch up with the share price.
The broader checks show a mixed picture rather than a clear bargain or clear overvaluation, with 3 of 6 metrics pointing to Zai Lab as relatively attractive on value.
The key issue for investors is whether Zai Lab's current market price still reflects too much optimism after years of weak long term returns, or whether the recent recovery in the stock is starting to align more reasonably with its fundamentals.
Balance Zai Lab's mixed five year record by comparing it with a hand picked group of stocks screened for quality and value using 47 high quality undervalued stocks.
P/S is usually a useful cross check for a company like Zai Lab where earnings are still negative and revenue is the cleaner anchor for valuation. On this measure, Zai Lab trades on a P/S of about 6.5x, which is above the peer average of roughly 5.0x but below the broader biotech industry average of about 13.2x.
The fair P/S ratio implied by the model is about 3.2x. That is roughly half of where the stock trades today, which suggests that, on this sales based yardstick, Zai Lab is currently valued at a higher level even after allowing for its specific growth prospects, risk profile and size. Relative to a hand picked peer group, the shares appear priced at a premium rather than offering a clear discount on current revenue.
On the preferred P/S multiple, Zai Lab stock currently screens as trading above its tailored fair value benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives pick up where Zai Lab's valuation puzzle leaves off. They spell out which revenue growth paths, margin levels and earnings profiles would need to play out for Zai Lab's stock to be worth meaningfully more or less than today. Rather than focusing on a single multiple or model, each one lays out the assumptions behind its view of fair value so you can compare those expectations with the results as they arrive.
Community views on Zai Lab are split between a high growth, global expansion story and a more cautious read on regulation and execution risk.
"Current market valuations do not appear to fully reflect Zai Lab's unique ability to access, acquire, and rapidly develop global first and China originated innovation..."
Read the full Bull Case to see why Zai Lab could be undervalued
"Stricter regulatory controls, pricing pressure, and reimbursement hurdles in China threaten sustainable revenue growth and delay earnings from new drug launches..."
Read the full Bear Case to see why Zai Lab could be overvalued
Do you think there's more to the story for Zai Lab? Head over to our Community to see what others are saying!
Zai Lab currently screens as overvalued on its tailored P/S benchmark, so the stock no longer looks obviously cheap on today's revenue base. The mixed valuation snapshot suggests investors are paying up for the possibility that future sales growth and margins eventually justify the premium. The key question from here is whether Zai Lab can convert its pipeline and partnerships into durable revenue and profit progress fast enough to support that higher multiple, or whether ongoing development and regulatory risks keep the stock looking expensive for longer.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZLAB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]